LAMELLASOME™ Platform TechnologiesLamellar bodies have an integral role in maintaining a healthy physiological balance throughout the body. LAMELLASOME™ technology has been engineered to mimic native Lamellar bodies optimising their characteristics for specific therapeutic purposes. As a result, LAMELLASOME™ now forms a range of patented platform technologies across chronic fibrosis, anti-infectives and a targeted therapeutic approach to serious rare diseases. Within each platform lies the potential to create multiple treatments tailored to address specific medical needs, improving efficacy and reducing side effects. LAMELLASOME™ Anti-fibrotic PlatformProducts disrupt the progression of fibrosis, the key pathology of progressive pulmonary fibrosisFind out moreLAMELLASOME™ Anti-infective PlatformProducts are designed to tackle serious bacterial infection and the global crisis of antimicrobial resistanceFind out moreLAMELLASOME™ Rare Disease PlatformProducts advancing novel treatments for rare diseases where there is high unmet clinical need.Find out moreLAMELLASOME™ ProductsLamellar Biomedical are pioneering product development using their proprietary LAMELLASOME™ technology in therapeutic applications that utilise the differing LAMELLASOME™ platform capabilities. The initial focus is on developing a portfolio of products, each with a significant impact on their respective therapeutic area. Anti-fibrosis Platform PFA-2 LAMELLASOME™ ALIPFA-1 LAMELLASOME™ Radioprotectant Anti-infective Platform CIA-1 LAMELLASOME™ Ocular AntibioticPIA-1 LAMELLASOME™ CF Antibiotic Rare Disease Platform LAMELLASOME™ IPF-RDLAMELLASOME™ CF-RDStrategic out-licensing, co-development and partneringLamellar would welcome strategic discussions to further advance development programs Investigate partnering opportunities
